As of May 23, 2025, Nautilus Biotechnology Inc (NAUT) reports a Current Ratio of 17.40.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Nautilus Biotechnology Inc's Current Ratio
Over recent years, Nautilus Biotechnology Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 17.40 |
| 2023-12-31 | 19.39 |
| 2022-12-31 | 27.53 |
| 2021-12-31 | 60.21 |
| 2020-12-31 | 25.90 |
This gradual decrease highlights how Nautilus Biotechnology Inc manages its short-term assets and liabilities over time.
Comparing Nautilus Biotechnology Inc's Current Ratio to Peers
To better understand Nautilus Biotechnology Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Nautilus Biotechnology Inc (NAUT) | 17.40 |
| Bio Rad Laboratories Inc (BIO) | 6.48 |
| 10X Genomics Inc (TXG) | 4.97 |
| Waters Corp (WAT) | 2.11 |
| Agilent Technologies Inc (A) | 2.09 |
| Illumina Inc (ILMN) | 1.77 |
Compared to its competitors, Nautilus Biotechnology Inc's Current Ratio is higher than all peers, indicating strong short-term financial flexibility but potentially excess cash that could be invested.